This Article Full Text Full Text (PDF) All Versions of this Article: 90/1/147    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soriano-Guillén, L. Articles by Carel, J. C. Search for Related Content PubMed PubMed Citation Articles by Soriano-Guillén, L. Articles by Carel, J. C. Related Collections Female Endocrinology Male Endocrinology

Adult Height after Ketoconazole Treatment in Patients with Familial Male-Limited Precocious Puberty

Department of Pediatric Endocrinology and Institut National de la Santé et de la Recherche Médicale, U561, Groupe Hospitalier Cochin-Saint Vincent de Paul and Faculté Cochin, Université Paris V (L.S.-G., J.L.C., J.C.C.); and Laboratory of Hormonal Biochemistry (N.L., M.R.), and Institut de Recherche Endocrinienne et Métabolique (N.L., M.R.), Groupe Hospitalier Cochin-Saint Vincent de Paul, 75014 Paris, France; and Department of Pediatrics, Centre Hospitalier Dr. Schaffner (G.C.), 62307 Lens, France

Address all correspondence and requests for reprints to: Dr. Jean-Claude Carel, Pediatric Endocrinology and Institut National de la Santé et de la Recherche Médicale, U561, Groupe Hospitalier Cochin-Saint Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, France. E-mail: carel{at}paris5.inserm.fr.

Familial male-limited precocious puberty is a rare cause of precocious puberty due to activating mutations of the LH receptor, leading to early onset virilization and short stature. Two therapeutic approaches have been proposed: the P450 cytochrome inhibitor ketoconazole or combined treatment with spironolactone and testolactone. Results on adult heights have not been reported to date after these two treatments, and in this study we present results from five patients treated with ketoconazole at a median dose of 16.2 mg/kg·d for a median of 6.2 yr. Adult height was 173 cm (median; interquartile range, 14), similar to target height (175 cm; interquartile range, 9) and significantly higher than pretreatment predicted height (165 cm; interquartile range, 12; P < 0.01). During treatment, 39 of 58 (68%) testosterone measurements were less than 0.5 ng/ml (1.7 nmol/liter), nine of 58 (15%) were between 0.5 and 1 ng/ml (3.5 nmol/liter), and 10 of 58 (17%) were above 1 ng/ml. We observed a physiological increase in GnRH-stimulated LH levels after the age of 10 yr, and none of the patients had early activation of the gonadotropic axis. Liver tolerance was excellent, and only one patient had a transient and modest increase in serum transaminases. We conclude that ketoconazole is an efficient and well tolerated long-term treatment of familial male-limited precocious puberty that should be proposed as a first line therapy.

This article has been cited by other articles:

				J.-C. Carel and J. Leger Precocious Puberty N. Engl. J. Med., May 29, 2008; 358(22): 2366 - 2377. [Full Text] [PDF]

				L. Soriano-Guillen, V. Mitchell, J.-C. Carel, P. Barbet, M. Roger, and N. Lahlou Activating Mutations in the Luteinizing Hormone Receptor Gene: A Human Model of Non-Follicle-Stimulating Hormone-Dependent Inhibin Production and Germ Cell Maturation J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3041 - 3047. [Abstract] [Full Text] [PDF]